Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Centessa Pharmaceuticals plc Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 HUSSAIN IQBAL J (General Counsel) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 7,520 shares @ $6.47, valued at $48.7k
10/03/2023 4 GRAINGER DAVID J (Chief Innovation Officer) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 4,700 shares @ $6.47, valued at $30.4k
10/03/2023 4 Weinhoff Gregory M (CFO) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 11,742 shares @ $6.47, valued at $76k
10/03/2023 4 SAHA SAURABH (CEO) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 36,263 shares @ $6.47, valued at $234.6k
10/03/2023 4 CHAO DAVID M (Chief Administrative Officer) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 10,419 shares @ $6.47, valued at $67.4k
10/03/2023 4 Bush Tia L (Chief Quality Officer) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 6,419 shares @ $6.47, valued at $41.5k
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023",
"MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/10/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study"
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Weinhoff Gregory M (CFO) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 11,742 shares @ $5.9001, valued at $69.3k
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
06/02/2023 4 YVER ANTOINE (EVP & Chairman of Development) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Sold 6,500 shares @ $4.4537, valued at $28.9k
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/26/2023 4 Bush Tia L (Chief Quality Officer) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Sold 5,000 shares @ $4.485, valued at $22.4k
Sold 3,000 shares @ $4.4801, valued at $13.4k
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/15/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/15/2023 ARS Form ARS - Annual Report to Security Holders:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 – Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline –"
05/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/01/2023 144 Form 144 - Report of proposed sale of securities:
04/04/2023 4 CHAO DAVID M (Chief Administrative Officer) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 6,969 shares @ $3.9, valued at $27.2k
04/04/2023 4 Weinhoff Gregory M (CFO) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 8,292 shares @ $3.9, valued at $32.3k
04/04/2023 4 Templeman Thomas (Chief Technology Officer) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 4,103 shares @ $3.9, valued at $16k
04/04/2023 4 SAHA SAURABH (CEO) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 22,013 shares @ $3.9, valued at $85.9k
04/04/2023 4 HUSSAIN IQBAL J (General Counsel) has filed a Form 4 on Centessa Pharmaceuticals plc
Txns: Paid exercise price by delivering 7,080 shares @ $3.9, valued at $27.6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy